Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2003-03-17
2011-12-13
Hill, Kevin K. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S372000
Reexamination Certificate
active
08075880
ABSTRACT:
In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.
REFERENCES:
patent: 4721096 (1988-01-01), Naughton et al.
patent: 5612211 (1997-03-01), Wilson et al.
patent: 5874301 (1999-02-01), Keller et al.
patent: 5980887 (1999-11-01), Isner et al.
patent: 2002/0037278 (2002-03-01), Ueno et al.
Iwasaki et al., Circulation 113(10): 1311-1325, 2006.
Hearse DJ, Eur. Heart J. 18 Suppl. A: A2-7, Jan. 1997.
Gratama et al, Cytometry 34: 128-142, 1998.
Steen and Egeland, Leuk. Lymph. 30: 23-30, 1998.
Rowland et al, Ann. Thorac. Surg. 60: 721-728, 1995.
Dengler et al, Herz 27(7): 598-610, 2002.
Itescu et al, J. Mol. Med 81: 288-296, 2003.
Rosenstrauch et al, Texas Heart Inst. J. 32: 339-347, 2005.
Schaper and Ito, Curr. Op. Biotech. 7: 635-640, 1996.
Deonarain, M., Expert Opin. Ther. Pat. 8: 53-69, 1998.
Verma and Somia, Nature 389: 239-242, 1997, *of record in IDS.
Verma and Weitzman, Annu. Rev. Biochem. 74:711-738, 2005.
Goncalves, BioEssays 27:506-517, 2005.
Gardlik et al., Med. Sci. Monit. 11:RA110-121, 2005.
Lechardeur and Lukacs, Current Gene Therapy 2: 183-194, 2002.
Cleland et al, April, Current Opinion in Biotechnology 12: 212-219, 2001.
Rudinger, Peptide Hormones, J.A. Parsons, ed., University Park Press, 1976.
Ngo et al., In Merz et al., ed. “The protein folding problem and tertiary structure prediction”, Birkhauser, 1994.
Benboubker et al, Exp. Hematol. 23: 1568-1573, 1995.
Younes, Curr. Mol. Med. 5(7): 609-613, 2005.
de Graaf et al, Anticancer Res. 15(6B):2851-2856, 1995.
Magennis, Br. J. Biomed. Sci. 55(3): 214-220; Abstract only.
Strauer et al, Circulation 106: 1913-1918, 2002; originally published online Sep. 3, 2002.
Kawamoto et al, Circulation 107:461-468, 2003; originally published online Dec. 30, 2002.
Kamihata et al, Arterioscler. Thromb. Vasc. Biol. 22:1804-1810, 2002; originally published online Sep. 26, 2002.
Bolwell et al, Bone Marrow Transplant. 14(6): 913-918, 1994; Abstract only.
Orlic et al, Nature 410:701-705, 2001.
Kawamoto et al, Circulation 103: 634-637, 2001.
Kamihata et al, Circulation 104: 1046-1052, 2001.
Fuchs et al, J. Am. Coll. Cardiol. 37(6): 1726-1732, 2001; available online Apr. 19, 2001.
Schechter et al, Bone Marrow Transplantation 13: 665-666, 1994.
Hormbrey et al, Clin. Cancer Res. 9:4332-4339, 2003.
Blindt et al, J. Am. Coll. Cardiol. 47(9):1786-1795, 2006.
Salven et al, Br. J. Cancer 74(1):69-72, 1996; Abstract only.
Bedikian et al, Med. Pediatr. Oncol. 4(2):149-157, 1978; Abstract only.
Grem et al, Am. J. Hematol. 38(3):245-247, 1991; Abstract only.
Woodlock et al, Am. J. Hematol. 59:246-248, 1998.
Schots et al, Bone Marrow Transplant 17(4):509-515, 1996.
Banai et al, Circulation 89:2183-2189, 1994.
Unger et al, Am. J. Physiol. 266:H1588-H1595, 1994.
Sato et al, Exp. Cell Res. 204:223-229, 1993.
Asahara et al., Science 275: 964-967 (1997) Int'1 Search Report dated Aug. 4, 1998.
XP-002059362—Asahara, et al. “In Vitro Evidence for Endothelial Cell Precursors in Peripheral Blood”.
XP-002059358—Asahara, et al. “Blood Cell Drived Endothelial Cell Precursor Can Participate . . . ”
Folkman and Shing,J. Biol. Chem. 267 (16), 10931-10934 (1992).
Baffour, et al.,J Vasc Surg, 16:181-91 (1992)).
Takeshita, et al.,Circulation, 90:228-234 (1994).
Takeshita, et al.,Laboratory Investigation, 75:487-502 (1996).
Tsurumi et al.,Circulation, vol. 94, No. 12, pp. 3281-3290 (1996).
Yanagisawa-Miwa, et al.,Science, 257:1401-1403 (1992).
Pu, et al.,J Surg Res, 54:575-83 (1993).
Isner, et al.,Lancet, 348:370 (1996)).
Takeshita, et al.,J Clin Invest, 93:662-70 (1994)).
H. Schnurch et al. Development 119: 957-968 (1993).
T. P. Yamaguchi et al. Development 118: 489-498 (1993).
C. Fennie et al. Blood 86: 4454-4467 (1995).
Asahara T. et al., “Blood Cell Derived Endothelial Cell Precursor Can Participate in Angiogenesis in Vivo.” Circulation, vol. 94, No. 8, Oct. 15, 1996.
Iwaguro et al. “Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration.” Circulation 105: 732-738 (2002).
Kalka et al., “Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects.” Circulation. 86: 1198-1202 (2000).
Freedman et al., “Therapeutic angiogenesis for ischemic cardiovascular disease.” Journal of Molecular and Cellular Cardiology 33:379-393 (2001).
Miller, N. et al., “Targeted vectors for gene therapy.” FASEB Journal. 9:190-199. Feb. 1995.
Verma, IM et al., “Gene therapy—promises, problems and prospects.” Nature. 389: 239-242. Sep. 1997.
Asahara et al., “Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo.”Circulation Nov. 1;92(9 Suppl):II 365-371. 1995.
Bik Falvi et al., “Angiogenic factors are hematopoietic growth factors and vice versa.” Leukema 8: 523-529. 1994.
Noishiki et al., “Autocrine angiogenic vascular prosthesis with bone marrow transplantation.” Nature Medicine Jan;2(1):90-3. 1996.
Shi et al., “Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog,” J Vas Surg 20: 546-557. 1994.
Crystal, RG. “Transfer of genes to humans: early lessons and obstacles to success.” Science. 270: Oct. 20, 1995;270(5235):404-10.
Asahara Takayuki
Isner Jeffrey M.
Isner, legal representative Linda
Losordo Douglas W.
Conlin David G.
Edwards Wildman Palmer LLP
Hill Kevin K.
Hunter-Ensor, Esq. Melissa
Steward St. Elizabeth's Medical Center of Boston, Inc.
LandOfFree
Compositions and methods for regulating angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for regulating angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for regulating angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314749